Tech Mahindra unveils AI powered pharmacovigilance solution with Nvidia’s agents | Benefits of generative ai in healthcare | What is generative ai google | Microsoft ai course | Turtles AI

Tech Mahindra, a global leader in technology consulting and digital solutions, has announced a collaboration with NVIDIA to develop an AI-based autonomous pharmacovigilance solution. This initiative aims to improve drug safety management by addressing the challenges of manual delays and data overload in the pharmaceutical industry.

Key Points:

• Automating pharmacovigilance processes to improve efficiency.
• Reducing response times by up to 40% and reducing operational costs by 25%.
• Improving data accuracy by 30%.
• Using AI agents to autonomously manage adverse reaction reports.

The solution is based on Tech Mahindra’s TENO framework, integrated with the NVIDIA AI Enterprise software platform, which includes advanced tools such as NVIDIA NeMo, NIM microservices and AI Blueprints. The combination automates and streamlines pharmacovigilance workflows, streamlining case acquisition, data transformation, quality assurance, and compliance management. Additionally, AI agents powered by large language models (LLMs) autonomously handle case classification, prioritization, and review of pharmacovigilance communications, reducing the risk of human error.

Nikhil Malhotra, Chief Innovation Officer and Global Head of AI and Emerging Technologies at Tech Mahindra, noted that the pharmaceutical industry handles massive volumes of data during clinical trials and post-launch. The collaboration with NVIDIA leverages generative AI and multi-agent systems to streamline the pharmacovigilance process, improving drug safety management, and developing multiple use cases for global customers.

The pharmacovigilance industry faces the challenge of managing more than 1,000 adverse drug reaction cases for major medicines on a daily basis. For example, when an adverse reaction is reported via email, the AI-powered solution can immediately identify, prioritize, and process the report, eliminating the need for human intervention that could cause delays and errors. This approach reduces response times by up to 40%, improves data accuracy by 30%, and reduces operating costs by 25%, ensuring timely case processing, regulatory compliance, and proactive risk mitigation. In this way, pharmacovigilance is moving from a reactive to a predictive approach.

John Fanelli, vice president of Enterprise Software at NVIDIA, highlighted how AI is ideal for monitoring medicines throughout their lifecycle, supporting safety. The integration of AI into Tech Mahindra’s TENO framework with NVIDIA AI Enterprise software enhances pharmacovigilance by augmenting human capabilities to identify potential safety issues more effectively.

Tech Mahindra has also expanded its TENO framework to include NVIDIA AI Enterprise, enriching it with custom AI agents to address a wide range of challenges in the industry. The framework integrates NVIDIA NeMo to accelerate the generative AI pipeline in data collection and curation, along with Tech Mahindra’s VerifAI solution for data validation and governance. Distributed training and model customization capabilities ensure that AI models continuously evolve, improving the accuracy of decision making.

This collaboration represents a significant step in the evolution of pharmacovigilance, combining Tech Mahindra’s expertise in digital solutions with NVIDIA’s leadership in AI to enable safer and more efficient drug management globally.